BACKGROUND: 5α-Reductase 2 deficiency (5ARD) is a known cause of 46,XY disorders of sex development (DSD). Traditionally, the diagnosis relies on dihydrotestosterone (DHT) measurement, but the results are often equivocal, potentially leading to misdiagnosis. We reviewed alternative approaches for diagnosis of 5ARD. METHODS: We conducted a retrospective review of the results of urinary steroid profiling (USP) by GC-MS and mutational analysis of SRD5A2 [steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2)] by PCR and direct DNA sequencing of all 46,XY DSD patients referred to our laboratory with biochemical and/or genetic findings compatible with 5ARD. We also performed a literature review on the laboratory findings of all 5ARD cases reported in the past 10 years. RESULTS: Of 16 patients diagnosed with 5ARD between January 2003 and July 2012, 15 underwent USP, and all showed characteristically low 5α- to 5β-reduced steroid metabolite ratios. Four patients had DHT measured, but 2 did not reach the diagnostic cutoff. In all 12 patients who underwent genetic analysis, 2 mutations of the SRD5A2 gene were detected to confirm the diagnosis. Twenty-four publications involving 149 patients with 5ARD were published in the review period. Fewer than half of these patients had DHT tested. Nearly 95% of them had the diagnosis confirmed genetically. CONCLUSIONS: 5ARD can be confidently diagnosed by USP at 3 months postnatally and confirmed by mutational analysis of SRD5A2. Interpretation of DHT results may be problematic and is not essential in the diagnosis of 5ARD. We propose new diagnostic algorithms for 46,XY DSD.
BACKGROUND: 5α-Reductase 2 deficiency (5ARD) is a known cause of 46,XY disorders of sex development (DSD). Traditionally, the diagnosis relies on dihydrotestosterone (DHT) measurement, but the results are often equivocal, potentially leading to misdiagnosis. We reviewed alternative approaches for diagnosis of 5ARD. METHODS: We conducted a retrospective review of the results of urinary steroid profiling (USP) by GC-MS and mutational analysis of SRD5A2 [steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2)] by PCR and direct DNA sequencing of all 46,XY DSDpatients referred to our laboratory with biochemical and/or genetic findings compatible with 5ARD. We also performed a literature review on the laboratory findings of all 5ARD cases reported in the past 10 years. RESULTS: Of 16 patients diagnosed with 5ARD between January 2003 and July 2012, 15 underwent USP, and all showed characteristically low 5α- to 5β-reduced steroid metabolite ratios. Four patients had DHT measured, but 2 did not reach the diagnostic cutoff. In all 12 patients who underwent genetic analysis, 2 mutations of the SRD5A2 gene were detected to confirm the diagnosis. Twenty-four publications involving 149 patients with 5ARD were published in the review period. Fewer than half of these patients had DHT tested. Nearly 95% of them had the diagnosis confirmed genetically. CONCLUSIONS: 5ARD can be confidently diagnosed by USP at 3 months postnatally and confirmed by mutational analysis of SRD5A2. Interpretation of DHT results may be problematic and is not essential in the diagnosis of 5ARD. We propose new diagnostic algorithms for 46,XY DSD.
Authors: John C Achermann; Sorahia Domenice; Tania A S S Bachega; Mirian Y Nishi; Berenice B Mendonca Journal: Nat Rev Endocrinol Date: 2015-05-05 Impact factor: 43.330
Authors: Thomas G Papathomas; Na Sun; Vasileios Chortis; Angela E Taylor; Wiebke Arlt; Susan Richter; Graeme Eisenhofer; Gerard Ruiz-Babot; Leonardo Guasti; Axel Karl Walch Journal: Histochem Cell Biol Date: 2019-02-06 Impact factor: 4.304
Authors: Karl-Heinz Storbeck; Lina Schiffer; Elizabeth S Baranowski; Vasileios Chortis; Alessandro Prete; Lise Barnard; Lorna C Gilligan; Angela E Taylor; Jan Idkowiak; Wiebke Arlt; Cedric H L Shackleton Journal: Endocr Rev Date: 2019-12-01 Impact factor: 19.871
Authors: Jonathan M Hazlehurst; Andrei I Oprescu; Nikolaos Nikolaou; Riccardo Di Guida; Annabel E K Grinbergs; Nigel P Davies; Robert B Flintham; Matthew J Armstrong; Angela E Taylor; Beverly A Hughes; Jinglei Yu; Leanne Hodson; Warwick B Dunn; Jeremy W Tomlinson Journal: J Clin Endocrinol Metab Date: 2015-11-17 Impact factor: 5.958
Authors: Nanis S Marzuki; Firman P Idris; Hannie D Kartapradja; Alida R Harahap; Jose R L Batubara Journal: Int J Endocrinol Date: 2019-12-01 Impact factor: 3.257